SCHEMBL3493993

SCHEMBL3493993

O=C1C2C3CCC(O3)C2C(=O)N1c1ccc(Cl)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
ALOX12 P18054 2/20 0.46
ALDH1A1 P00352 5/20 0.43
NOTUM Q6P988 1/20 0.40
BCL2A1 Q16548 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.39
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
GRM4 Q14833 1/20 0.37
GRM1 Q13255 1/20 0.37
HTT P42858 1/20 0.37
AKR1C3 P42330 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3189406 0.85 L3MBTL1 (0.55) L3MBTL1SMN1; SMN2LMNAGRM4GRM1
SCHEMBL3189399 0.85 L3MBTL1 (0.55) L3MBTL1SMN1; SMN2LMNAGRM4GRM1
SCHEMBL4081657 0.78 L3MBTL1 (0.51) L3MBTL1SMN1; SMN2LMNAGRM4GRM1
SCHEMBL4081661 0.78 L3MBTL1 (0.51) L3MBTL1SMN1; SMN2LMNAGRM4GRM1
SCHEMBL3493827 0.78 HSD17B10 (0.56) L3MBTL1KMT2AMEN1MAPTALOX12
SCHEMBL3181723 0.77 L3MBTL1 (0.50) L3MBTL1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL3181734 0.77 L3MBTL1 (0.50) L3MBTL1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL5511033 0.77 GRM4 (0.54) KMT2AMEN1MAPTALOX12SMN1; SMN2
SCHEMBL3189141 0.77 L3MBTL1 (0.57) L3MBTL1KMT2AMEN1MAPTALDH1A1
SCHEMBL3189157 0.77 L3MBTL1 (0.57) L3MBTL1KMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US claimed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP disclosed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C L3MBTL1 598/4885KMT2A 1199/4885MEN1 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.